Insight Capital Research & Management’s Jazz Pharmaceuticals JAZZ Stock Holding History

Insight Capital Research & Management’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q3	–	Sell	-24,438	Closed	-$3.59M	–	131
2014 Q2	$3.59M	Buy	+24,438	New	+$3.39M	0.82%	50
2014 Q1	–	Sell	-46,533	Closed	-$5.89M	–	137
2013 Q4	$5.89M	Sell	46,533 -71,744	-61%	-$7.42M	1.32%	26
2013 Q3	$10.7M	Buy	118,277 +52,781	+81%	+$4.26M	2.6%	3
2013 Q2	$4.5M	Buy	+65,496	New	+$4M	1.17%	20

Other funds holding JAZZ

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

LPC

Lone Pine Capital Greenwich, Connecticut $12.5B AUM 54.4% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

WBC

Westpac Banking Corp Sydney, Australia $1.44B AUM 28.5% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Insight Capital Research & Management's JAZZ Position: Q3 2014 in Review

Insight Capital Research & Management sold out of Jazz Pharmaceuticals (JAZZ) in Q3 2014, closing a stake of 24,438 shares — an estimated $3.59M sold.

Insight Capital Research & Management first reported a position in JAZZ in Q2 2013 and held it in 4 quarters. The position peaked at $10.7M in Q3 2013. 325 funds tracked by Wall St. Rank hold JAZZ as of Q3 2014.

Insight Capital Research & Management reported no remaining Jazz Pharmaceuticals position as of Q3 2014 after selling out during the quarter.
Insight Capital Research & Management sold 24,438 Jazz Pharmaceuticals shares in Q3 2014, an estimated $3.59M.
Insight Capital Research & Management first reported a position in Jazz Pharmaceuticals in Q2 2013 and held it in 4 quarters.
Insight Capital Research & Management's Jazz Pharmaceuticals position peaked at $10.7M in Q3 2013.
325 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q3 2014.

Based on Insight Capital Research & Management's 13F filing for Q3 2014, filed 6 Nov 2014.